Vaccine and Vaccination Practice Questions

Q: Pneumococcal vaccine is prepared from ?

Capsular polysaccharide. ***Capsular polysaccharide*** - The **polysaccharide capsule** of *Streptococcus pneumoniae* is the primary virulence factor, protecting the bacteria from phagocytosis. - Vaccines, such as **PCV13** (pneumococcal conjugate vaccine) and **PPSV23** (pneumococcal polysaccharide vaccine), are designed targeting these capsular polysaccharides to elicit a protective immune response. *Cell surface antigen* - While bacteria possess various **cell surface antigens**, not all are immunogenic or provide protective immunity as effectively as the capsular polysaccharides for *S. pneumoniae*. - For pneumococcus, the **capsule** is the most critical surface component for vaccine development due to its role in virulence and serotype specificity. *From exotoxin* - *S. pneumoniae* primarily causes disease through its **polysaccharide capsule** and other bacterial components, not through the production of an **exotoxin** that would be targeted by a vaccine. - Vaccines developed from exotoxins (e.g., diphtheria or tetanus toxoids) target specific toxins, which is not the mechanism for pneumococcal vaccines. *From M protein* - **M protein** is a major virulence factor for *Streptococcus pyogenes* (Group A Strep), not *Streptococcus pneumoniae*. - Vaccines targeting M protein are associated with **Group A Streptococcus** infections, for protection against diseases like rheumatic fever.

Q: What component is included in the vaccine against N-meningitidis?

Capsular polysaccharide (polysaccharide vaccine). ***Capsular polysaccharide (polysaccharide vaccine)*** - *Neisseria meningitidis* vaccines commonly include **capsular polysaccharides** from different serogroups (A, C, Y, W-135) to elicit a protective immune response. - These polysaccharides act as antigens, stimulating the production of **antibodies** that can neutralize the bacteria. - **Conjugate vaccines** combine polysaccharides with carrier proteins to improve immunogenicity, especially in infants and young children. *Killed whole-cell vaccine* - **Killed whole-cell vaccines** are not used for *N. meningitidis* due to potential reactogenicity and the availability of more effective targeted antigens. - **Polysaccharide and conjugate vaccines** are the established formulations for meningococcal disease prevention. *Outer membrane protein (OMP)* - **Outer membrane proteins (OMPs)** are specifically used in **serogroup B vaccines** (e.g., Bexsero, Trumenba) due to the poor immunogenicity of the serogroup B polysaccharide capsule. - However, for serogroups A, C, Y, and W-135, **capsular polysaccharide** remains the primary vaccine component. *Live attenuated vaccine* - **Live attenuated vaccines** are not used for *N. meningitidis* as they pose risks of reversion to virulence and are unnecessary given the effectiveness of polysaccharide-based vaccines. - Meningococcal vaccines rely on **subunit approaches** (polysaccharides, conjugates, OMPs) rather than live organisms.

Q: What is the type of vaccine produced from the SA-14-14-2 strain of the Japanese encephalitis virus?

Live attenuated vaccine. ***Live attenuated vaccine*** - The **SA-14-14-2 strain** is specifically engineered to be a **weakened, non-pathogenic** form of the Japanese encephalitis virus. - This allows it to replicate in the host without causing disease, stimulating a **strong and long-lasting immune response**. *Inactivated vaccine* - An **inactivated vaccine** uses a whole virus that has been **killed** (inactivated) to prevent it from replicating. - While the SA-14-14-2 strain is used for a vaccine, it is not an inactivated one; it is designed to be **live but attenuated**. *Killed virus vaccine* - A **killed virus vaccine** is another term for an **inactivated vaccine**, where the virus's ability to replicate is destroyed, usually by chemical means. - The SA-14-14-2 vaccine functions by introducing a **live, weakened virus** that can still replicate, rather than a killed one. *Subunit vaccine* - A **subunit vaccine** contains only specific **antigenic components** of the virus, rather than the entire virus. - The SA-14-14-2 vaccine utilizes the **entire virus** in an attenuated form, making it distinct from a subunit vaccine.

Q: Vaccines are available against which types of meningococcus?

Type A, B, C, W, and Y. ***Type A, B, C, W, and Y*** - Vaccines are currently available against **all five major meningococcal serogroups**: A, B, C, W-135, and Y. - **Meningococcal conjugate vaccines (MenACWY)** provide protection against serogroups A, C, W-135, and Y, and are widely used globally. - **Meningococcal B vaccines (MenB)** such as Bexsero and Trumenba specifically target serogroup B, which is a leading cause of meningococcal disease in developed countries. - Combined, these vaccines provide comprehensive coverage against the most epidemiologically important meningococcal serogroups worldwide. *Type A* - While vaccines against **meningococcus type A** do exist (as part of conjugate vaccines), this option is incomplete as it excludes the other important serogroups (B, C, W, Y) for which vaccines are also available. *Type B* - **Type B vaccines** are available and important, particularly in developed countries where serogroup B causes significant disease burden. - However, this option alone is insufficient because vaccines also effectively target other serogroups (A, C, W, Y). *Type A, B, and C* - This option is incomplete because it omits **serogroups W and Y**, for which conjugate vaccines (MenACWY) are readily available and widely used. - The question asks which types vaccines are *available* against, not which are most common, making this an incorrect answer.

Q: Which type of vaccine is used for chicken pox?

Live vaccine. ***Live vaccine*** - The chickenpox vaccine (Varicella vaccine) is a **live-attenuated vaccine**, meaning it contains a weakened form of the **Varicella-zoster virus** (Oka strain). - This weakened virus can still replicate in the body, stimulating a strong and long-lasting immune response similar to natural infection but without causing severe disease. *Killed vaccine* - **Killed (inactivated) vaccines** use viruses or bacteria that have been inactivated through heat or chemicals, making them unable to replicate. - While effective for some diseases (e.g., inactivated polio, influenza), they typically require **multiple doses** and might provide less durable immunity compared to live vaccines. *Conjugated vaccine* - **Conjugated vaccines** are designed to improve the immune response to polysaccharide antigens (e.g., bacterial capsules) by linking them to a carrier protein. - This technology is primarily used for **bacterial infections** like *Haemophilus influenzae* type b (Hib) or pneumococcal disease, not viral illnesses like chickenpox. *Toxoid vaccine* - **Toxoid vaccines** contain inactivated bacterial toxins (toxoids) rather than the whole organism. - Examples include **tetanus and diphtheria vaccines**, which protect against diseases caused by bacterial toxins, not viral infections like chickenpox.

Q: Recipients of meningococcal polyvalent vaccine are not protected from which serogroup of Neisseria meningitidis with the vaccine available today?

Serogroup B. ***Serogroup B*** - The **meningococcal polyvalent vaccine** (e.g., MenACWY) primarily targets serogroups A, C, W-135, and Y. - **Serogroup B** is not adequately covered by these polysaccharide-based vaccines due to its capsular polysaccharide being poorly immunogenic and structurally similar to human host antigens, requiring different vaccine technologies (e.g., recombinant protein vaccines like Bexsero and Trumenba). *Serogroup A* - **Serogroup A** is one of the target serogroups included in the standard **meningococcal polyvalent vaccines** (MenACWY), offering protection against this specific strain. - Vaccines for serogroup A have been crucial in controlling epidemics, particularly in the African meningitis belt. *Serogroup C* - **Serogroup C** is another key component covered by the **meningococcal polyvalent vaccines** (MenACWY), providing protection against this common cause of meningococcal disease. - Conjugate vaccines against serogroup C have significantly reduced disease incidence in many countries. *Serogroup Y* - **Serogroup Y** is one of the serogroups included in the **meningococcal polyvalent vaccines** (MenACWY), conferring protection against infections caused by this strain. - Serogroup Y is increasingly recognized as a cause of meningococcal disease in certain regions, including the United States.

Q: Which route is the H1N1 live vaccine administered by?

Intranasal. ***Intranasal*** - The **live attenuated influenza vaccine (LAIV)**, often referred to as the "nasal spray flu vaccine," is administered intranasally. - This route allows the vaccine to replicate in the **nasal passages**, mimicking natural infection and stimulating a localized immune response. *Intramuscular* - The **inactivated influenza vaccine (IIV)**, or the "flu shot," is administered intramuscularly. - This route delivers the vaccine into the **muscle tissue** to stimulate a systemic immune response without local replication. *Subcutaneous* - Subcutaneous administration is used for some vaccines, but it is **not the standard route** for either live or inactivated influenza vaccines. - This route delivers the vaccine into the **fatty tissue** just under the skin. *Oral* - Oral administration is typically used for live vaccines that need to replicate in the **gastrointestinal tract**, such as the rotavirus vaccine. - It is **not an appropriate route** for influenza vaccines as the virus needs to stimulate respiratory immunity.

Q: The following are live attenuated vaccines, except:

Pertussis. ***Pertussis*** - The **pertussis vaccine** is an **inactivated (subunit) vaccine**, not a live attenuated vaccine. It contains purified components of the *Bordetella pertussis* bacteria. - Due to the high risk of severe complications, especially in infants, an inactivated vaccine is preferred to avoid any risk of active infection from a live vaccine. *BCG* - The **BCG (Bacille Calmette-Guérin) vaccine** is a **live attenuated vaccine** used to prevent tuberculosis. - It contains a live, weakened strain of *Mycobacterium bovis*. *Oral typhoid* - The **oral typhoid vaccine (Ty21a)** is a **live attenuated vaccine** designed to protect against *Salmonella Typhi*. - It consists of a live, weakened strain of the typhoid bacterium, taken orally. *Measles* - The **measles vaccine** (often given as part of the MMR vaccine) is a **live attenuated vaccine**. - It contains a weakened form of the measles virus, eliciting a strong immune response.

Q: Which strain is used in the Mumps vaccine?

Jeryl Lynn strain. ***Jeryl Lynn strain*** - The **Jeryl Lynn strain** is the most commonly used and safest viral strain for the mumps vaccine, having been isolated in 1963. - This strain is known for its **attenuation** (weakened form) without losing its immunogenicity, providing effective protection against mumps. *Edmonston Zagreb strain* - The **Edmonston-Zagreb strain** is primarily used in some measles vaccines, not mumps vaccines. - It is a highly effective measles vaccine strain, but its application is specific to measles immunization. *RA 27/3 strain* - The **RA 27/3 strain** is exclusively used in the rubella vaccine to protect against rubella (German measles). - It is a live-attenuated virus that elicits a strong immune response against rubella. *Oka strain* - The **Oka strain** is the main attenuated strain used in the varicella vaccine to prevent chickenpox. - It is derived from a wild-type varicella-zoster virus and is effective in preventing or mitigating chickenpox.

Q: Meningococcal vaccine is prepared from which of the following organisms?

Neisseria meningitidis. ***Neisseria meningitidis*** - The meningococcal vaccine is specifically designed to prevent infections caused by **_Neisseria meningitidis_**, which is the primary cause of meningococcal meningitis and sepsis. - The vaccine typically targets the **polysaccharide capsule** of specific serogroups of _N. meningitidis_, such as A, C, W, and Y, or includes components for serogroup B in newer vaccines. *Mycobacterium bovis* - _Mycobacterium bovis_ is the causative agent of **bovine tuberculosis** and can also cause tuberculosis in humans, mainly through the consumption of contaminated dairy products. - The **BCG vaccine** (Bacillus Calmette-Guérin) is derived from an attenuated strain of _Mycobacterium bovis_ and is used to prevent tuberculosis, not meningococcal disease. *Mycobacterium tuberculosis* - _Mycobacterium tuberculosis_ is the bacterium responsible for causing **tuberculosis** in humans, a respiratory disease primarily affecting the lungs. - There is currently no widely available vaccine specifically derived from _M. tuberculosis_ for human use; prevention relies on identifying and treating infected individuals and using the BCG vaccine. *Clostridium perfringens* - _Clostridium perfringens_ is a bacterium known to cause **gas gangrene** (a severe form of soft tissue infection) and various types of food poisoning. - While it can produce toxins and cause significant disease, there is no vaccine available or commonly used for _Clostridium perfringens_ infections in humans.

Question 1

Pneumococcal vaccine is prepared from ?

Accepted Answer

Capsular polysaccharide

Answer

Cell surface antigen

Answer

Exotoxin

Answer

M protein

Question 2

What component is included in the vaccine against N-meningitidis?

Accepted Answer

Capsular polysaccharide (polysaccharide vaccine)

Answer

Killed whole-cell vaccine

Answer

Outer membrane protein (OMP)

Answer

Live attenuated vaccine

Question 3

What is the type of vaccine produced from the SA-14-14-2 strain of the Japanese encephalitis virus?

Accepted Answer

Live attenuated vaccine

Answer

Subunit vaccine

Answer

Inactivated vaccine

Answer

Killed virus vaccine

Question 4

Vaccines are available against which types of meningococcus?

Accepted Answer

Type A, B, C, W, and Y

Answer

Type A

Answer

Type B

Answer

Type A, B, and C

Question 5

Which type of vaccine is used for chicken pox?

Accepted Answer

Live vaccine

Answer

Killed vaccine

Answer

Conjugated vaccine

Answer

Toxoid vaccine

Question 6

Recipients of meningococcal polyvalent vaccine are not protected from which serogroup of Neisseria meningitidis with the vaccine available today?

Accepted Answer

Serogroup B

Answer

Serogroup C

Answer

Serogroup Y

Answer

Serogroup A

Question 7

Which route is the H1N1 live vaccine administered by?

Accepted Answer

Intranasal

Answer

Intramuscular

Answer

Oral

Answer

Subcutaneous

Question 8

The following are live attenuated vaccines, except:

Accepted Answer

Pertussis

Answer

BCG

Answer

Oral typhoid

Answer

Measles

Question 9

Which strain is used in the Mumps vaccine?

Accepted Answer

Jeryl Lynn strain

Answer

Edmonston Zagreb strain

Answer

RA 27/3 strain

Answer

Oka strain

Question 10

Meningococcal vaccine is prepared from which of the following organisms?

Accepted Answer

Neisseria meningitidis

Answer

Mycobacterium tuberculosis

Answer

Mycobacterium bovis

Answer

Clostridium perfringens

Vaccine and Vaccination — MCQs

Vaccine and Vaccination — MCQs

On this page

Practice by Chapter

Want unlimited practice?